Rina-S for Gastrointestinal Cancer

(RAINFOL-09 Trial)

This trial tests the effectiveness of a new treatment called Rina-S for individuals with gastrointestinal (GI) cancer. All participants will receive the Rina-S treatment, with no placebos involved. Eligible participants should have GI cancer that has spread or cannot be surgically removed and should have tried other treatments without success. The trial requires regular clinic visits for tests and monitoring. If the treatment proves beneficial and safe, participants may continue as long as the study remains active. As a Phase 2 trial, this study focuses on assessing the treatment's effectiveness in an initial, smaller group of people.

The trial requires that you stop taking any anticancer agents at least 28 days before starting the study treatment. The protocol does not specify about other medications, so it's best to discuss your current medications with the study team.

Research has shown that Rina-S has been generally safe in earlier studies. For participants with heavily treated endometrial cancer, Rina-S demonstrated promising results in fighting tumors while maintaining a safety profile consistent with past findings. Another study found that participants tolerated Rina-S well. The side effects during treatment were manageable and not severe. Importantly, no new unexpected safety concerns emerged. Additionally, there were no reports of eye problems or lung disease, common concerns with some cancer treatments. Overall, Rina-S appears well tolerated in previous clinical trials.¹²³⁴⁵

Rina-S is unique because it targets gastrointestinal cancer through a novel mechanism of action that sets it apart from traditional treatments like chemotherapy and targeted therapies. Unlike most treatments that focus on killing cancer cells directly, Rina-S works by enhancing the immune system's ability to recognize and attack cancer cells, which could lead to more effective and potentially longer-lasting results. Researchers are excited about Rina-S because it not only offers a new approach to treating GI cancer but also has the potential to reduce side effects often associated with conventional therapies.

Research has shown that Rina-S yields promising results for treating various types of cancer. In earlier studies, Rina-S controlled the disease in all patients who had tried several treatments before, with tumors either shrinking or ceasing to grow. Some studies also found that 50% of patients responded well, with a few experiencing complete disappearance of their cancer. Rina-S targets and stops the growth of specific cancer cells, which might make it effective for gastrointestinal cancers as well. These findings suggest Rina-S could be a promising treatment option for people with GI cancer. Participants in this trial will receive Rina-S to evaluate its effectiveness specifically for gastrointestinal cancer.¹²³⁴⁶